CURA headed into its Q1 2026 earnings with short sellers already retreating — and the results gave them little reason to return.
The company posted Q1 EPS of $0.09, against a consensus estimate of $(0.06) — a $0.15 beat. Revenue came in at $324.2M, ahead of the $316.0M forecast. The stock closed 6.3% higher on Tuesday, adding to gains of 4.4% on the week and a remarkable 41% rally over the past month. The profit swing is the clearest signal yet that Curaleaf's restructuring and cost-cutting work has begun to flow through to the bottom line.
Short interest had already been thinning out ahead of the print. Shorts fell roughly 10% over the past month to just 0.45% of the free float — a level too low to carry meaningful squeeze risk. Borrow costs have been subdued at around 3%, and the lending market is very loose with availability well above supply constraints. That picture was consistent with the broader short-score reading of 31, down from the low-to-mid 30s in late April, and well below its 52-week lending-demand peak. Short sellers, in aggregate, had already stepped back before Tuesday's catalyst.
The debate heading into the print centred on whether Curaleaf could actually generate a profit after years of heavy losses. The EV/EBITDA multiple of around 12x suggested the market was pricing in a modest recovery, but the negative trailing PE reflected lingering scepticism about earnings quality. The 90-day EPS momentum factor ranked in the 94th percentile of the universe — pointing to a consistent run of upward estimate revisions — while the 30-day reading ranked far lower at the 22nd percentile, hinting that near-term analyst enthusiasm had cooled somewhat before the release. That divergence made the actual beat more impactful.
The ownership picture adds a layer of context. Co-founder Joseph Lusardi added nearly 2M shares in March, reported at a 1.06% stake. CFO Edward Kremer built his position by over 624,000 shares in the most recently reported quarter. The Chief Legal Officer Peter Clateman sold roughly 117,000 shares across two dates in April — at prices well below where the stock now trades — a transaction that looks more like routine tax-driven selling than a bearish signal, given the stock has since rallied sharply.
All eyes now turn to whether Curaleaf's Q2 revenue trajectory and margin profile can sustain the valuation re-rating that this quarter's profit swing has set in motion.
See the live data behind this article on ORTEX.
Open CURA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
